Chinese Medical Sciences Journal ›› 2019, Vol. 34 ›› Issue (4): 292-296.doi: 10.24920/003487

• Case Report • Previous Articles     Next Articles

Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer

Zhang Ling1, Sun Lei1, Mu Xiaoyan2, Ji Youxin2, *()   

  1. 1. Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China
    2. Department of Oncology, the Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong 266042, China
  • Received:2018-07-05 Accepted:2018-12-13 Published:2019-12-31 Online:2019-11-12
  • Contact: Ji Youxin

A 61-year-old Chinese woman was diagnosed as primary pulmonary adenocarcinoma of left superior lobe with epidermal growth factor receptor (EGFR) 19 del mutation positive. Treatment with icotinib was given, but her disease progressed after 6 months remission. CT-guide needle biopsy for the new lesion in inferior lobe of left lung demonstrated intrapulmonary metastasis, and EGFR gene panel by Amplification Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) confirmed EGFR T790M mutation. Treatment with osimertinib was initiated. After 2 months remission, the disease progressed. Re-biopsy was performed for the tumor in the inferior lobe of left lung, and ARMS-PCR demonstrated no other gene mutation except EGFR 19 del. Icotinib was re-challenged, but disease progressed continuously. Bevacizumab was added, and partial response was achieved after 2-cycle of combination therapy. The non-small cell lung cancer (NSCLC) in this case maintained EGFR activating mutation and lost EGFR T790M mutation was a genetic change after osimertinib treatment. This case suggests the re-challenge of the first-generation EGFR-TKIs combined with bevacizumab may overcome the tumor resistance and prolong survival of NSCLC patient.

Key words: Epidermal growth factor receptor-tyrosine kinase inhibitor, resistant mutation, non-small cell lung cancer, bevacizumab

Copyright © 2021 Chinese Academy of Medical Sciences.  京公安备110402430088  京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 


Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1